{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:29:42Z","timestamp":1791044982851,"version":"4.1.0"},"reference-count":61,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adult T-cell leukemia\/lymphoma (ATL) is an aggressive and fatal disease. We have examined 32 patients with smoldering, chronic, lymphoma and acute leukemia using Affymetrix HG-U133A2.0 arrays. Using the BRB array program, we identified genes differentially expressed in leukemia cells compared with normal lymphocytes. Several unique genes were identified that were overexpressed in leukemic cells, including TNFSF11, RGS13, MAFb, CSPG2, C\/EBP-\u03b1, and TCF4; 200 of the most highly overexpressed ATL genes were analyzed by the Pathway Studio, version 4.0 program. ATL leukemia cells were characterized by an increase in genes linked to \u201ccentral\u201d genes CDC2\/cyclin B1, SYK\/LYN, proliferating cell nuclear antigen, and BIRC5. Because of its potential therapeutic importance, we focused our studies on the regulation and function of BIRC5, whose expression was increased in 13 of 14 leukemia samples. TCF4 reporter assays and transfection of DN-TCF4 demonstrated that TCF4 regulates BIRC5 gene expression. Functionally, transfection of ATL cells with BIRC5 shRNA decreased BIRC5 expression and cell viability 80%. Clinical treatment of ATL patients with Zenapax or bortezomib decreased BIRC5 expression and cell viability. These experiments represent the first direct experimental evidence that BIRC5 plays an important role in ATL cell viability and provides important insight into ATL genesis and potential targeted therapies.<\/jats:p>","DOI":"10.1182\/blood-2008-08-175901","type":"journal-article","created":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T21:49:34Z","timestamp":1231451374000},"page":"4016-4026","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":65,"title":["Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability"],"prefix":"10.1182","volume":"113","author":[{"given":"Cynthia A.","family":"Pise-Masison","sequence":"first","affiliation":[{"name":"Laboratory of Cellular Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Radonovich","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dohoney","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[{"name":"Metabolism Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"O'Mahony","sequence":"additional","affiliation":[{"name":"Metabolism Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Trepel","sequence":"additional","affiliation":[{"name":"Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"Metabolism Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Janik","sequence":"additional","affiliation":[{"name":"Metabolism Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Brady","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111723270533600_B1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0065-230X(03)01003-0","article-title":"Seizing of T cells by human T-cell leukemia\/lymphoma virus type 1.","volume":"89","author":"Franchini","year":"2003","journal-title":"Adv Cancer Res"},{"key":"2019111723270533600_B2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1742-4690-1-20","article-title":"Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity.","volume":"1","author":"Azran","year":"2004","journal-title":"Retrovirology"},{"key":"2019111723270533600_B3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13550280390194028","article-title":"Human T-cell lymphotropic virus type I and neurological diseases.","volume":"9","author":"Nagai","year":"2003","journal-title":"J Neurovirol"},{"key":"2019111723270533600_B4","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2741\/1414","article-title":"Immunopathogenesis of HTLV-I associated neurologic disease: molecular, histopathologic, and immunologic approaches.","volume":"9","author":"Takenouchi","year":"2004","journal-title":"Front Biosci"},{"key":"2019111723270533600_B5","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases.","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"key":"2019111723270533600_B6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ijc.2910430214","article-title":"Modelling the risk of adult T-cell leukemia\/lymphoma in persons infected with human T-lymphotropic virus type I.","volume":"43","author":"Murphy","year":"1989","journal-title":"Int J Cancer"},{"key":"2019111723270533600_B7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1349-7006.1989.tb02289.x","article-title":"Multi-step carcinogenesis model for adult T-cell leukemia.","volume":"80","author":"Okamoto","year":"1989","journal-title":"Jpn J Cancer Res"},{"key":"2019111723270533600_B8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.leu.2402458","article-title":"Role of tumor suppressor genes in the development of adult T cell leukemia\/lymphoma (ATLL).","volume":"16","author":"Hatta","year":"2002","journal-title":"Leukemia"},{"key":"2019111723270533600_B9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.V79.2.477.477","article-title":"Mutations of the p53 gene in adult T-cell leukemia.","volume":"79","author":"Sakashita","year":"1992","journal-title":"Blood"},{"key":"2019111723270533600_B10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0168-1702(01)00286-6","article-title":"Treatment of adult T-cell leukaemia\/lymphoma: current strategy and future perspectives.","volume":"78","author":"Bazarbachi","year":"2001","journal-title":"Virus Res"},{"key":"2019111723270533600_B11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10428199809057597","article-title":"Adult T-cell leukemia\/lymphoma in London: clinical experience of 21 cases.","volume":"31","author":"Pawson","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"2019111723270533600_B12","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.1988.6.7.1088","article-title":"Major prognostic factors of adult patients with advanced T-cell lymphoma\/leukemia.","volume":"6","author":"Shimoyama","year":"1988","journal-title":"J Clin Oncol"},{"key":"2019111723270533600_B13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0145-2126(93)90061-O","article-title":"Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia\/lymphoma.","volume":"17","author":"Tsukasaki","year":"1993","journal-title":"Leuk Res"},{"key":"2019111723270533600_B14","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1038\/sj.onc.1208979","article-title":"Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy.","volume":"24","author":"Taylor","year":"2005","journal-title":"Oncogene"},{"key":"2019111723270533600_B15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V72.5.1805.1805","article-title":"Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.","volume":"72","author":"Waldmann","year":"1988","journal-title":"Blood"},{"key":"2019111723270533600_B16","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia.","volume":"82","author":"Waldmann","year":"1993","journal-title":"Blood"},{"key":"2019111723270533600_B17","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"key":"2019111723270533600_B18","first-page":"6453","article-title":"Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"2019111723270533600_B19","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1182\/blood-2005-01-0335","article-title":"Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine\/IFN-\u03b1-refractory adult T-cell leukemia.","volume":"106","author":"Mone","year":"2005","journal-title":"Blood"},{"key":"2019111723270533600_B20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.leukres.2005.05.008","article-title":"Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.","volume":"30","author":"Ravandi","year":"2006","journal-title":"Leuk Res"},{"key":"2019111723270533600_B21","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1089\/08892220050193164","article-title":"Gene expression array of HTLV type 1-infected T cells: up-regulation of transcription factors and cell cycle genes.","volume":"16","author":"de La Fuente","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019111723270533600_B22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.onc.1202405","article-title":"Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation.","volume":"18","author":"Harhaj","year":"1999","journal-title":"Oncogene"},{"key":"2019111723270533600_B23","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1038\/sj.onc.1204513","article-title":"Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-kappaB activation.","volume":"20","author":"Ng","year":"2001","journal-title":"Oncogene"},{"key":"2019111723270533600_B24","first-page":"3562","article-title":"Transcription profile of cells infected with human T-cell leukemia virus type I compared with activated lymphocytes.","volume":"62","author":"Pise-Masison","year":"2002","journal-title":"Cancer Res"},{"key":"2019111723270533600_B25","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/sj.onc.1206549","article-title":"Cellular transformation by the HTLV-I Tax protein, a jack-of-all-trades.","volume":"22","author":"Gatza","year":"2003","journal-title":"Oncogene"},{"key":"2019111723270533600_B26","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1038\/sj.onc.1206551","article-title":"Human T-cell leukemia virus type I and adult T-cell leukemia.","volume":"22","author":"Matsuoka","year":"2003","journal-title":"Oncogene"},{"key":"2019111723270533600_B27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ijc.20028","article-title":"Identifying progression-associated genes in adult T-cell leukemia\/lymphoma by using oligonucleotide microarrays.","volume":"109","author":"Tsukasaki","year":"2004","journal-title":"Int J Cancer"},{"key":"2019111723270533600_B28","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2004-03-1222","article-title":"Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia.","volume":"105","author":"Sasaki","year":"2005","journal-title":"Blood"},{"key":"2019111723270533600_B29","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2003-12-4174","article-title":"HTLV-I Tax induces a novel interaction between p65\/RelA and p53 that results in inhibition of p53 transcriptional activity.","volume":"104","author":"Jeong","year":"2004","journal-title":"Blood"},{"key":"2019111723270533600_B30","unstructured":"National Center for Biotechnology Information\n          GEO\n          Accessed January 7, 2009\n          \n            http:\/\/www.ncbi.nlm.nih.gov\/geo"},{"key":"2019111723270533600_B31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1349-7006.2005.00050.x","article-title":"Tumor immunity against adult T-cell leukemia.","volume":"96","author":"Kannagi","year":"2005","journal-title":"Cancer Sci"},{"key":"2019111723270533600_B32","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1359\/JBMR.040314","article-title":"Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia.","volume":"19","author":"Okada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2019111723270533600_B33","doi-asserted-by":"crossref","first-page":"16768","DOI":"10.1074\/jbc.M200751200","article-title":"Functional characterization of the G protein regulator RGS13.","volume":"277","author":"Johnson","year":"2002","journal-title":"J Biol Chem"},{"key":"2019111723270533600_B34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/1541-7786.MCR-04-0189","article-title":"Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation.","volume":"3","author":"Creighton","year":"2005","journal-title":"Mol Cancer Res"},{"key":"2019111723270533600_B35","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1074\/jbc.M007542200","article-title":"Versican interacts with chemokines and modulates cellular responses.","volume":"276","author":"Hirose","year":"2001","journal-title":"J Biol Chem"},{"key":"2019111723270533600_B36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1096\/fj.04-3000fje","article-title":"Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers.","volume":"19","author":"Mauri","year":"2005","journal-title":"FASEB J"},{"key":"2019111723270533600_B37","doi-asserted-by":"crossref","first-page":"15632","DOI":"10.1073\/pnas.242597299","article-title":"Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.","volume":"99","author":"Yoon","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111723270533600_B38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1182\/blood.V100.3.982","article-title":"Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin.","volume":"100","author":"Chung","year":"2002","journal-title":"Blood"},{"key":"2019111723270533600_B39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1749-6632.1995.tb26671.x","article-title":"IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor.","volume":"766","author":"Taniguchi","year":"1995","journal-title":"Ann NY Acad Sci"},{"key":"2019111723270533600_B40","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1080\/1042819021000039956","article-title":"Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology.","volume":"43","author":"Nakayama","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2019111723270533600_B41","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.1128\/JVI.00739-06","article-title":"Human T-cell leukemia virus type 1 tax dysregulates beta-catenin signaling.","volume":"80","author":"Tomita","year":"2006","journal-title":"J Virol"},{"key":"2019111723270533600_B42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/1074-7613(95)90081-0","article-title":"Protein tyrosine kinase Syk is associated with and activated by the IL-2 receptor: possible link with the c-myc induction pathway.","volume":"2","author":"Minami","year":"1995","journal-title":"Immunity"},{"key":"2019111723270533600_B43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.immuni.2006.05.004","article-title":"Unraveling the pros and cons of interferon-gamma gene regulation.","volume":"24","author":"Young","year":"2006","journal-title":"Immunity"},{"key":"2019111723270533600_B44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/jir.2006.26.473","article-title":"Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.","volume":"26","author":"Wang","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"2019111723270533600_B45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/138920006778017768","article-title":"Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients.","volume":"7","author":"Brandacher","year":"2006","journal-title":"Curr Drug Metab"},{"key":"2019111723270533600_B46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0165-2427(98)00136-6","article-title":"Short-termed expression of interleukin-12 during experimental BLV infection may direct disease progression to persistent lymphocytosis.","volume":"64","author":"Yakobson","year":"1998","journal-title":"Vet Immunol Immunopathol"},{"key":"2019111723270533600_B47","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2003-11-3967","article-title":"Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.","volume":"104","author":"Mitra-Kaushik","year":"2004","journal-title":"Blood"},{"key":"2019111723270533600_B48","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/eji.1830210815","article-title":"The human interferon-gamma gene contains an inducible promoter that can be transactivated by tax I and II.","volume":"21","author":"Brown","year":"1991","journal-title":"Eur J Immunol"},{"key":"2019111723270533600_B49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1385\/IR:31:3:231","article-title":"STAT4: a critical regulator of inflammation in vivo.","volume":"31","author":"Kaplan","year":"2005","journal-title":"Immunol Res"},{"key":"2019111723270533600_B50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.0105-2896.2004.00211.x","article-title":"Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4.","volume":"202","author":"Watford","year":"2004","journal-title":"Immunol Rev"},{"key":"2019111723270533600_B51","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.2741\/1900","article-title":"Posttranslational modifications of Bcl2 family members: a potential therapeutic target for human malignancy.","volume":"11","author":"Basu","year":"2006","journal-title":"Front Biosci"},{"key":"2019111723270533600_B52","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4161\/cc.3.9.1093","article-title":"An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy.","volume":"3","author":"Zangemeister-Wittke","year":"2004","journal-title":"Cell Cycle"},{"key":"2019111723270533600_B53","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"key":"2019111723270533600_B54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2006.12.020","article-title":"Survivin: a promising tumor biomarker.","volume":"249","author":"Duffy","year":"2007","journal-title":"Cancer Lett"},{"key":"2019111723270533600_B55","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1182\/blood-2005-08-3423","article-title":"Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines.","volume":"107","author":"Che","year":"2006","journal-title":"Blood"},{"key":"2019111723270533600_B56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1207\/S15327914NC4402_12","article-title":"Resveratrol induces down-regulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy.","volume":"44","author":"Hayashibara","year":"2002","journal-title":"Nutr Cancer"},{"key":"2019111723270533600_B57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1532\/IJH97.04031","article-title":"Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias.","volume":"80","author":"Sugahara","year":"2004","journal-title":"Int J Hematol"},{"key":"2019111723270533600_B58","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood-2005-02-0735","article-title":"Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir.","volume":"107","author":"Dewan","year":"2006","journal-title":"Blood"},{"key":"2019111723270533600_B59","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2404129","article-title":"Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor.","volume":"20","author":"Sanda","year":"2006","journal-title":"Leukemia"},{"key":"2019111723270533600_B60","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1158\/0008-5472.CAN-04-1253","article-title":"Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis.","volume":"64","author":"van Doorn","year":"2004","journal-title":"Cancer Res"},{"key":"2019111723270533600_B61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery.","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat Rev Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/17\/4016\/1309229\/zh801709004016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/17\/4016\/1309229\/zh801709004016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T23:27:25Z","timestamp":1574033245000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/17\/4016\/25602\/Gene-expression-profiling-of-ATL-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,23]]},"references-count":61,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-08-175901","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,23]]}}}